141 related articles for article (PubMed ID: 26339915)
21. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
[TBL] [Abstract][Full Text] [Related]
22. Clinical and Cost Implications of Universal Versus Locally Advanced-Stage and Advanced-Stage-Only Molecular Testing for Epidermal Growth Factor Receptor Mutations and Anaplastic Lymphoma Kinase Rearrangements in Non-Small Cell Lung Carcinoma: A Tertiary Academic Institution Experience.
Sauter JL; Butnor KJ
Arch Pathol Lab Med; 2016 Apr; 140(4):358-61. PubMed ID: 27028394
[TBL] [Abstract][Full Text] [Related]
23. Molecular targets in the treatment of non-small-cell lung cancer: is there hope on the horizon?
Carter CA; Nations JA; Lazarus A
Postgrad Med; 2014 Nov; 126(7):139-48. PubMed ID: 25387222
[TBL] [Abstract][Full Text] [Related]
24. Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer.
Bozzetti C; Naldi N; Nizzoli R; Azzoni C; Bortesi B; Zobbi V; Bottarelli L; Tiseo M; Gasparro D; Majori M; De Filippo M; Ardizzoni A
Lung Cancer; 2013 Apr; 80(1):35-8. PubMed ID: 23352033
[TBL] [Abstract][Full Text] [Related]
25. ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization.
Yamamoto S; Korn RL; Oklu R; Migdal C; Gotway MB; Weiss GJ; Iafrate AJ; Kim DW; Kuo MD
Radiology; 2014 Aug; 272(2):568-76. PubMed ID: 24885982
[TBL] [Abstract][Full Text] [Related]
26. Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer.
Lozano MD; Labiano T; Echeveste J; Gurpide A; Martín-Algarra S; Zhang G; Sharma A; Palma JF
Cancer Cytopathol; 2015 Apr; 123(4):230-6. PubMed ID: 25529460
[TBL] [Abstract][Full Text] [Related]
27. Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1).
Beau-Faller M; Degeorges A; Rolland E; Mounawar M; Antoine M; Poulot V; Mauguen A; Barbu V; Coulet F; Prétet JL; Bièche I; Blons H; Boyer JC; Buisine MP; de Fraipont F; Lizard S; Olschwang S; Saulnier P; Prunier-Mirebeau D; Richard N; Danel C; Brambilla E; Chouaid C; Zalcman G; Hainaut P; Michiels S; Cadranel J
J Thorac Oncol; 2011 Jun; 6(6):1006-15. PubMed ID: 21532509
[TBL] [Abstract][Full Text] [Related]
28. ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy.
Rosell R; Karachaliou N; Wolf J; Ou SH
Lancet Respir Med; 2014 Dec; 2(12):966-8. PubMed ID: 25466349
[No Abstract] [Full Text] [Related]
29. Rare Complex Mutational Profile in an ALK Inhibitor-resistant Non-small Cell Lung Cancer.
Azzato EM; Deshpande C; Aikawa V; Aggarwal C; Alley E; Jacobs B; Morrissette J; Daber R
Anticancer Res; 2015 May; 35(5):3007-12. PubMed ID: 25964588
[TBL] [Abstract][Full Text] [Related]
30. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
[TBL] [Abstract][Full Text] [Related]
31. Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS.
Guisier F; Salaün M; Lachkar S; Lamy A; Piton N; Obstoy B; Sabourin JC; Thiberville L
Respirology; 2016 May; 21(4):718-26. PubMed ID: 27099101
[TBL] [Abstract][Full Text] [Related]
32. Methodological recommendations for the diagnostics of EGFR gene mutations and ALK gene rearrangement in the selection of non-small-cell lung cancer patients to molecularly targeted therapies.
Krawczyk P; Chorostowska-Wynimko J; Dziadziuszko R; Jassem J; Krzakowski M; Langfort R; Puacz E; Wasąg B; Wojas-Krawczyk K
Pneumonol Alergol Pol; 2014; 82(5):437-44. PubMed ID: 25133812
[TBL] [Abstract][Full Text] [Related]
33. Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study.
de Marinis F; Ardizzoni A; Fontanini G; Grossi F; Cappuzzo F; Novello S; Santo A; Lorusso V; Cortinovis D; Iurlaro M; Galetta D; Gridelli C;
Clin Lung Cancer; 2014 Sep; 15(5):338-45.e1. PubMed ID: 24925809
[TBL] [Abstract][Full Text] [Related]
34. Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis.
DiStasio M; Chen Y; Rangachari D; Costa DB; Heher YK; VanderLaan PA
Clin Lung Cancer; 2017 Sep; 18(5):e349-e356. PubMed ID: 28377205
[TBL] [Abstract][Full Text] [Related]
35. Deep ion sequencing of amplicon adapter ligated libraries: a novel tool in molecular diagnostics of formalin fixed and paraffin embedded tissues.
Becker K; Vollbrecht C; Koitzsch U; Koenig K; Fassunke J; Huss S; Nuernberg P; Heukamp LC; Buettner R; Odenthal M; Altmueller J; Merkelbach-Bruse S
J Clin Pathol; 2013 Sep; 66(9):803-6. PubMed ID: 23618693
[TBL] [Abstract][Full Text] [Related]
36. Non-small cell lung cancer--genetic predictors.
Koudelakova V; Kneblova M; Trojanec R; Drabek J; Hajduch M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Jun; 157(2):125-36. PubMed ID: 23733083
[TBL] [Abstract][Full Text] [Related]
37. New and emerging targeted treatments in advanced non-small-cell lung cancer.
Hirsch FR; Suda K; Wiens J; Bunn PA
Lancet; 2016 Sep; 388(10048):1012-24. PubMed ID: 27598681
[TBL] [Abstract][Full Text] [Related]
38. Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.
Cottini F; Lautenschlaeger T
Cancer J; 2013; 19(3):263-71. PubMed ID: 23708073
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status.
Kalikaki A; Koutsopoulos A; Hatzidaki D; Trypaki M; Kontopodis E; Stathopoulos E; Mavroudis D; Georgoulias V; Voutsina A
Lung Cancer; 2010 Jul; 69(1):110-5. PubMed ID: 19854533
[TBL] [Abstract][Full Text] [Related]
40. Analytic inquiry: Molecular testing in lung cancer.
Zakowski MF
Cancer Cytopathol; 2017 Jun; 125(S6):470-476. PubMed ID: 28609002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]